We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
-18.5%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$144M
AUM Growth
-$35.5M
Cap. Flow
+$4.68M
Cap. Flow %
3.25%
Top 10 Hldgs %
99.43%
Holding
11
New
1
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
EDIT icon
Editas Medicine
EDIT
+$2.76M
2
EPIX
ESSA Pharma
EPIX
+$1.98M

Top Sells

Rank Stock Value
1
CBAY
Cymabay Therapeutics
CBAY
+$54.4K

Sector Composition

Rank Sector Weight
1 Healthcare 66.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JUNO
1
DELISTED
Juno Therapeutics, Inc.
JUNO
$46.8M 32.48%
1,229,512
– –
PRTK
2
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$32.4M 22.51%
2,138,872
– –
EGLT
3
DELISTED
Egalet Corporation
EGLT
$19.3M 13.39%
2,814,928
– –
KYNB
4
Kyntra Bio
KYNB
$28.5M
$17.5M 12.14%
32,887
– –
NBRV
5
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$10.3M 7.12%
4,584
– –
EPIX
6
DELISTED
ESSA Pharma
EPIX
$5.51M 3.83%
84,848
+30,303
+56% +$1.98M
PVLA
7
Palvella Therapeutics
PVLA
$1.98B
$4.72M 3.27%
31,049
– –
EDIT icon
8
Editas Medicine
EDIT
$399M
$3.63M 2.52%
+105,007
New +$2.76M
TARA icon
9
Protara Therapeutics
TARA
$226M
$1.94M 1.34%
6,250
– –
DRNA
10
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.2M 0.83%
223,457
– –
CBAY
11
DELISTED
Cymabay Therapeutics
CBAY
$818K 0.57%
606,100
-43,900
-7% -$54.4K

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q1 2016 Portfolio in Review

As of Q1 2016, Omega Fund Management held 11 positions worth $144M, down 20% from $180M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Omega Fund Management deployed $4.68M of net new capital in Q1 2016, opening 1 new position and adding to 1 existing holding. Its largest new stake was Editas Medicine: 105,007 shares worth $3.63M.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, down from 68% a quarter earlier.

On the sell side, the largest reduction was Cymabay Therapeutics, an estimated $54.4K trimmed.

  • Omega Fund Management's largest Q1 2016 buy was Editas Medicine: 105,007 shares worth $3.63M.
  • Omega Fund Management added most to ESSA Pharma in Q1 2016, an estimated $1.98M increase.
  • Omega Fund Management's biggest Q1 2016 reduction was Cymabay Therapeutics, cutting an estimated $54.4K.
  • Omega Fund Management's ten largest holdings make up 99% of its $144M portfolio in Q1 2016.
  • Omega Fund Management opened 1 new position and closed 0 in Q1 2016.
  • Omega Fund Management's portfolio value fell 20% quarter-over-quarter to $144M.

Based on Omega Fund Management's 13F filing for Q1 2016, filed 2 May 2016.